InVivo Therapeutics Announces Appointment of Daniel R. Marshak, PhD to Its Board of Directors

<0> InVivo TherapeuticsBrian Luque, 617-863-5535Investor Relations </0>

 today announced the appointment of Daniel R Marshak, PhD to its Board of Directors. Dr. Marshak most recently served as Senior Vice President and Chief Scientific Officer for PerkinElmer, Inc. He led PerkinElmer’s research and development functions while helping to drive growth across the organization.

Prior to joining PerkinElmer in 2006, Dr. Marshak was Vice President and Chief Technology Officer, Biotechnology, for Cambrex Corporation. He previously served as Senior Vice President and Chief Scientific Officer for Osiris Therapeutics, Inc., where he led stem cell research and development from inception to late-stage clinical trials. Before working at Osiris, he was a Senior Staff Investigator at Cold Spring Harbor Laboratory in New York.

Dr. Marshak has received numerous awards for scientific and academic achievements and is named as inventor on six issued U.S. patents. He currently serves on the International Society for Stem Cell Research Global Advisory Council and has also served on their Board of Directors.

Dr. Marshak is the author of more than 100 scientific publications, including one textbook, and has been the editor of five monographs. He recently held an appointment as Adjunct Associate Professor at the Johns Hopkins University School of Medicine, and previously taught graduate biochemistry as an Assistant Professor at the State University of New York.

Dr. Marshak received his Bachelor of Arts degree in biochemistry and molecular biology from Harvard University, and holds a doctorate in biochemistry and cell biology from The Rockefeller University.

Mark Perrin, InVivo’s CEO, said, “We are thrilled to have Dan join the InVivo team. His deep rooted commitment to scientific rigor and excellence, combined with his extensive industry experience will be invaluable as we move this Company forward. ”

John McCarthy, InVivo’s Chairman of the Board, added, “As we look to broaden and expand our Board of Directors in parallel with our other initiatives, we welcome Dan to the Board and believe he will be a valuable addition in assisting us to successfully reach our full potential.”

InVivo Therapeutics Holdings Corp. is a pioneering biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who then was at Boston Children’s Hospital and now is affiliated with Massachusetts General Hospital. In 2011 the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit .

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.